Serum Antibodies to the HPV16 Proteome As Biomarkers for Head and Neck Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Jun 10

PMID 21654689

Citations 34

Authors

K S Anderson

J Wong

G DSouza

A B Riemer

J Lorch

R Haddad

S I Pai

J Longtine

M McClean

J LaBaer

K T Kelsey

M Posner

Affiliations

Soon will be listed here.

Abstract

Background: Human papillomavirus (HPV) type 16 is associated with oropharyngeal carcinomas (OPC). Antibodies (Abs) to HPV16 E6 and E7 oncoproteins have been detected in patient sera; however, Abs to other early HPV-derived proteins have not been well explored.

Methods: Antibodies to the HPV16 proteome were quantified using a novel multiplexed bead assay, using C-terminal GST-fusion proteins captured onto Luminex beads. Sera were obtained from untreated patients with OPC (N=40), partners of patients with HPV16+ OPC (N=11), and healthy controls (N=50).

Results: Oropharyngeal carcinomas patients with known virus-like capsid particle+ Abs had elevated serum Abs to HPV16 E1, E2, E4, E6, and E7, and L1 antibody levels, but not E5. The ratios of specific median fluorescence intensity to p21-GST compared with controls were E1: 50.7 vs 2.1; E4: 14.6 vs 1.3; E6: 11.3 vs 2.4; E7: 43.1 vs 2.6; and L1: 10.3 vs 2.6 (each P≤0.01). In a validation cohort, HPV16 E1, E2, and E7 antibody levels were significantly elevated compared with healthy control samples (P≤0.02) and partners of OPC patients (P≤0.01).

Conclusion: Patients with HPV16+ OPC have detectable Abs to E1, E2, and E7 proteins, which are potential biomarkers for HPV-associated OPC.

Citing Articles

Circulating Tumor Cells in Oral Cancer.

Sharma Y, Gawande M, Reche A, Bardia M Cureus. 2024; 16(1):e51684.

PMID: 38318575 PMC: 10839405. DOI: 10.7759/cureus.51684.

The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer.

Conarty J, Wieland A Viruses. 2023; 15(6).

PMID: 37376596 PMC: 10301020. DOI: 10.3390/v15061296.

Current Infections of the Orofacial Region: Treatment, Diagnosis, and Epidemiology.

Tahmasebi E, Keshvad A, Alam M, Abbasi K, Rahimi S, Nouri F Life (Basel). 2023; 13(2).

PMID: 36836626 PMC: 9966653. DOI: 10.3390/life13020269.

Comparative Microbiomics Analysis of Antimicrobial Antibody Response between Patients with Lung Cancer and Control Subjects with Benign Pulmonary Nodules.

Shome M, Gao W, Engelbrektson A, Song L, Williams S, Murugan V Cancer Epidemiol Biomarkers Prev. 2022; 32(4):496-504.

PMID: 36066883 PMC: 10494706. DOI: 10.1158/1055-9965.EPI-22-0384.

Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis.

Hibbert J, Halec G, Baaken D, Waterboer T, Brenner N Cancers (Basel). 2021; 13(12).

PMID: 34208476 PMC: 8234521. DOI: 10.3390/cancers13123010.

References

Smith E, Pawlita M, Rubenstein L, Haugen T, Hamsikova E, Turek L . Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer. 2009; 127(1):111-7. DOI: 10.1002/ijc.25015. View

Kirnbauer R, Hubbert N, Wheeler C, Becker T, Lowy D, Schiller J . A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994; 86(7):494-9. PMC: 3935441. DOI: 10.1093/jnci/86.7.494. View

Waterboer T, Sehr P, Michael K, Franceschi S, Nieland J, Joos T . Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005; 51(10):1845-53. DOI: 10.1373/clinchem.2005.052381. View

Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P . Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95(23):1772-83. DOI: 10.1093/jnci/djg107. View

Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E . Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol. 2003; 188(1):49-55. DOI: 10.1067/mob.2003.98. View

Reuschenbach M, Waterboer T, Wallin K, Einenkel J, Dillner J, Hamsikova E . Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer. 2008; 123(11):2626-31. DOI: 10.1002/ijc.23837. View

Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey K . Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002; 8(10):3187-92. View

Markowitz L, Sternberg M, Dunne E, McQuillan G, Unger E . Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009; 200(7):1059-67. DOI: 10.1086/604729. View

van Houten V, Snijders P, van den Brekel M, Kummer J, Meijer C, van Leeuwen B . Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer. 2001; 93(2):232-5. DOI: 10.1002/ijc.1313. View

10.

Smith J, Kowalski R, Esser M, Brown M, Bryan J . Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008; 4(2):134-42. DOI: 10.4161/hv.4.2.5261. View

11.

Ramachandran N, Raphael J, Hainsworth E, Demirkan G, Fuentes M, Rolfs A . Next-generation high-density self-assembling functional protein arrays. Nat Methods. 2008; 5(6):535-8. PMC: 3070491. DOI: 10.1038/nmeth.1210. View

12.

Smith E, Ritchie J, Pawlita M, Rubenstein L, Haugen T, Turek L . Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer. 2006; 120(4):825-32. DOI: 10.1002/ijc.22330. View

13.

Wilson V, West M, Woytek K, Rangasamy D . Papillomavirus E1 proteins: form, function, and features. Virus Genes. 2002; 24(3):275-90. DOI: 10.1023/a:1015336817836. View

14.

Di Bonito P, Grasso F, Mochi S, Accardi L, Dona M, Branca M . Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect Agent Cancer. 2006; 1:6. PMC: 1660559. DOI: 10.1186/1750-9378-1-6. View

15.

Schwartz S, Yueh B, McDougall J, Daling J, Schwartz S . Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg. 2001; 125(1):1-9. DOI: 10.1067/mhn.2001.116979. View

16.

Agoston E, Robinson S, Mehra K, Birch C, Semmel D, Mirkovic J . Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. Am J Clin Pathol. 2010; 134(1):36-41. DOI: 10.1309/AJCP1AAWXE5JJCLZ. View

17.

Wang S, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez A . Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer. 2004; 91(7):1269-74. PMC: 2409899. DOI: 10.1038/sj.bjc.6602088. View

18.

Dillner J, Wiklund F, Lenner P, Eklund C, Schiller J, Hibma M . Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer. 1995; 60(3):377-82. DOI: 10.1002/ijc.2910600318. View

19.

Luevano M, Bernard H, Barrera-Saldana H, Trevino V, Garcia-Carranca A, Villa L . High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology. 2010; 405(1):31-40. PMC: 2914195. DOI: 10.1016/j.virol.2010.05.011. View

20.

Dunne E, Unger E, Sternberg M, McQuillan G, Swan D, Patel S . Prevalence of HPV infection among females in the United States. JAMA. 2007; 297(8):813-9. DOI: 10.1001/jama.297.8.813. View